A Phase 1b/2 clinical trial evaluating Oncternal Therapeutics‘ investigational therapy cirmtuzumab in combination with Imbruvica (ibrutinib) for the treatment of B-cell malignancies has dosed its first patient with mantle cell lymphoma. The trial is ... Read more